Skip to main content
TipRanks
Go Ultimate75% OFF

Outlook Therapeutics (OTLK) Stock Statistics & Valuation Metrics

1,837 Followers

Total Valuation

Outlook Therapeutics has a market cap or net worth of $100.54M. The enterprise value is $224.61M.

Market Cap
$100.54M
Enterprise Value
$224.61M

Share Statistics

Outlook Therapeutics has 243,447,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
243,447,560
Owned by Insiders
10.51%
Owned by Institutions
7.12%

Financial Efficiency

Outlook Therapeutics’s return on equity (ROE) is 1.94 and return on invested capital (ROIC) is -2357.61%.

Return on Equity (ROE)
1.94
Return on Assets (ROA)
-3.36
Return on Invested Capital (ROIC)
-2357.61%
Return on Capital Employed (ROCE)
2.46
Revenue Per Employee
83.15K
Profits Per Employee
-3.67M
Employee Count
17
Asset Turnover
0.08
Inventory Turnover
0.23

Valuation Ratios

The current PE Ratio of Outlook Therapeutics is -0.38. Outlook Therapeutics’s PEG ratio is 0.00.

PE Ratio
-0.38
PS Ratio
-86.44
PB Ratio
-5.43
Price to FCF
-1.76
Price to Operating Cash Flow
-0.99
PEG Ratio
0.00

Income Statement

In the last 12 months, Outlook Therapeutics had revenue of 1.41M and earned -62.42M in profits. Earnings per share was -1.79.

Revenue
1.41M
Gross Profit
657.21K
Operating Income
-67.06M
Pretax Income
-63.98M
Net Income
-62.42M
EBITDA
-63.58M
Earnings Per Share (EPS)
-1.79

Cash Flow

In the last 12 months, operating cash flow was -57.13M and capital expenditures 0, giving a free cash flow of -57.13M billion.

Operating Cash Flow
-57.13M
Free Cash Flow
-57.13M
Free Cash Flow per Share
-0.42

Dividends & Yields

Outlook Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-56.82%
Earnings Yield
-108.23%

Stock Price Statistics

Beta
1.90
52-Week Price Change
-71.90%
50-Day Moving Average
0.56
200-Day Moving Average
0.67
Relative Strength Index (RSI)
32.59
Average Volume (3m)
6.72M

Important Dates

Outlook Therapeutics upcoming earnings date is Dec 18, 2026, TBA (Not Confirmed).

Last Earnings Date
Aug 14, 2026
Next Earnings Date
Dec 18, 2026
Ex-Dividend Date
―

Financial Position

Outlook Therapeutics as a current ratio of 0.38, with Debt / Equity ratio of -93.81%

Current Ratio
0.38
Quick Ratio
0.31
Debt to Market Cap
1.11
Net Debt to EBITDA
-0.35
Interest Coverage Ratio
-236.86

Taxes

In the past 12 months, Outlook Therapeutics has paid -1.55M in taxes.

Income Tax
-1.55M
Effective Tax Rate
0.02

Enterprise Valuation

Outlook Therapeutics EV to EBITDA ratio is -1.73, with an EV/FCF ratio of -1.89.

EV to Sales
-92.62
EV to EBITDA
-1.73
EV to Free Cash Flow
-1.89
EV to Operating Cash Flow
-1.89

Balance Sheet

Outlook Therapeutics has $11.24M in cash and marketable securities with $18.43M in debt, giving a net cash position of -$7.19M billion.

Cash & Marketable Securities
$11.24M
Total Debt
$18.43M
Net Cash
-$7.19M
Net Cash Per Share
-$0.03
Tangible Book Value Per Share
-$0.08

Margins

Gross margin is 195.64%, with operating margin of 4783.05%, and net profit margin of 5254.81%.

Gross Margin
195.64%
Operating Margin
4783.05%
Pretax Margin
5384.94%
Net Profit Margin
5254.81%
EBITDA Margin
5353.27%
EBIT Margin
5362.21%

Analyst Forecast

The average price target for Outlook Therapeutics is $10.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$10.50
Price Target Upside
2442.37% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
2
AI Score
48